Paper

Inhibition of the human two‐pore domain potassium channel, TREK‐1, by fluoxetine and its metabolite norfluoxetine

Published Mar 1, 2005 · DOI · Louise E. Kennard, J. Chumbley, K. M. Ranatunga

British Journal of Pharmacology

195

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro StudyHighly Cited

Study Snapshot

Fluoxetine and its metabolite, norfluoxetine, are potent inhibitors of the human two-pore domain potassium channel TREK-1, which may have important consequences in depression treatment.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Inhibition of the human two‐pore domain potassium channel, TREK‐1, by fluoxetine and its metabolite norfluoxetine

References

Citations